Nanoliposomal irinotecan for use in treating small cell lung cancer
US11318131B2 · kind B2 · utility
3Cited by
65References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 17, 2017 |
| Grant date | May 3, 2022 |
| Priority date | — |
| Expiry date | May 17, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K33/243
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel therapies for the treatment of small cell lung cancer (SCLC) include the administration of an antineoplastic therapy consisting of liposomal irinotecan administered once every two weeks, optionally including the administration of other non-antineoplastic agents to the patient such as the administration of a corticosteroid and an anti-emetic to the patient prior to the administration of the irinotecan liposome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.